Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

Hepatology

Volumn 49, Issue 6, 2009, Pages 1838-1846

  Bacon, Bruce R ^a   Shiffman, Mitchell L ^b   Mendes, Flavia ^c   Ghalib, Reem ^d   Hassanein, Tarek ^e   Morelli, Giuseppe ^f   Joshi, Shobha ^g   Rothstein, Kenneth ^h   Kwo, Paul ⁱ   Gitlin, Norman ^j  

^a Saint Louis University   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d METHODIST DALLAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MARION BESSIN LIVER RESEARCH CENTER   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONSENSUS INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBASPHERE; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; APPETITE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BLURRED VISION; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LEUKOCYTE COUNT; LEUKOPENIA; LIVER BIOPSY; LIVER FIBROSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PAIN; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REINFECTION; RETREATMENT; RIGOR; SALIVA; SIDE EFFECT; SINUSITIS; SORE THROAT; SWEATING; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; VOMITING; WEIGHT; XEROSTOMIA;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETREATMENT; RIBAVIRIN; TREATMENT FAILURE;

EID: 66949176133     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22871     Document Type: Article

References (20)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.
3. Fartoux L, Degos F, Trepo C, Goria O, Cales P, Tran A, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: A randomized trial. Clin Gastroenterol Hepatol 2007;5:502-507.
4. Helbling B, Jochum W, Stamenic I, Knopfli M, Cerny A, Borovicka J, et al. HCV-related advanced fibrosis/cirrhosis: Randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006;13:762-769.
5. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: A multicenter, retrospective cohort study of 1124 patients. Liver Int 2007; 27:186-191.
6. Shiffman ML. Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Curr Gastroenterol Rep 2006;8:46-52.
7. Keeffe EB. Future treatment of chronic hepatitis C. Antivir Ther 2007;12: 1015-1025.
8. DiBisceglie A., Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-2441.
9. Jensen DB, Freilich B, Andreone P, DiBisceglie A, Brandão-Mello CE, Reddy KR, et al. Pegylated interferon alfa-2a (40kD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kD)/ RBV: Final efficacy and safety outcomes of the REPEAT study [abstract LB4]. HEPATOLOGY 2007;46(Suppl):291A-292A.
10. Kaiser S, Hass H, Gregor M. Successful retreatment of peginterferon non-responder patients with chronic hepatitis C with high dose consensus interferon induction therapy [Abstract 125]. Gastroenterology 2004; 126(Suppl 2):A-668.
11. Kaiser S, Hass HG, Bissinger L, Gregor M. Comparison of daily consensus interferon versus peginterferon alfa 2a extended therapy of 72 weeks for peginterferon/ribavirin relapse patients with chronic hepatitis C [Abstract S1060]. Gastroenterology 2006;130(Suppl 2):A-784.
12. Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML. Peginterferon alfa-2a/ ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2008;27:433-440.
13. Hassanein T, Ghalib R, Zein N, Rothstein KD, Joshi SN, Kwo PY, et al. Analysis of relapse rates in pegylated interferon and ribavirin non-responders treated with daily consensus interferon and ribavirin [Abstract 1319]. HEPATOLOGY 2007;46:A1319.
14. Leevy CB. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci 2008;53:1961-1966.
15. Afdhal NH, Levine R, Brown RJ, Freilich B, O'Brien M, Brass C. Colchicine versus peg-interferon alfa 2b long term therapy: Results of the 4 year COPILOT trial [Abstract 3]. J Hepatol 2008;48(Suppl):S4.
16. Jensen D, Di Bisceglie A, Gitlin N, Freilich B, Reddy K, Feinman V, et al. Peginterferon alfa-2a (40KD) plus ribavirin (RBV) in pegylated interferon alfa-2b (12KD)/ribavirin non-responders: Week 12 efficacy and safety outcomes of the REPEAT study. Gastroenterology 2006;130;T1800.
17. Jensen D, Di Bisceglie A, Gitlin N, Freilich B, Reddy K, Feinman V, et al. Type of response to prior pegylated interferon alfa-2b (12kd)/rbv predicts subsequent response to retreatment with peginterferon alfa-2a (40KD)/RBV. Gastroenterology 2008;134:S1937.
18. Kaiser S, Boecher W, Lutze B, Sauter B, Bissinger L, Werner C, et al. Treatment of peginterferon/ribavirin nonresponders with daily dosing of consensus interferon and ribavirin: Preliminary results of the German Consensus Interferon Multicenter Study [Abstract 1306]. HEPATOLOGY 2007;46(Suppl):817A.
19. Ghalib RH, Levine CD, Friedman DA, Rashdan S, Schwartz AG, Weinstein J. Consensus interferon plus ribavirin therapy in patients who are nonresponders or relapsers to prior PEG IFN plus ribavirin. Gastroenterology 2007;46:M1874.
20. Harrison SA. Small molecules and novel treatment for chronic hepatitis C virus infection. Am J Gastroenterol 2007;102:2332-2338.